To help migraine patients — and sell more medicines — major drugmakers turn to telehealth

In 2021, Katey Frederking had reached the end of her rope. The 29-year-old was struggling with frequent migraines, which started after a concussion from a fall on an icy patch near her home in Chicago. The medications she had been prescribed weren’t working, her doctor wasn’t listening, and she was facing several months of wait time before she could see a new neurologist. 

So she took to Google and quickly signed up with Cove, a telehealth company focused on migraine care. Cove helped her get a prescription for a triptan, a class of migraine drugs available since the ’90s. When that wasn’t enough, Cove recommended one of a new class of migraine drugs that target a nerve cell protein called calcitonin gene-related peptide, or CGRP. 

“I knew exactly what I wanted and needed, and it provided me with exactly it,” Frederking told STAT about her experience with Cove. The anti-CGRP drug, Nurtec, “absolutely changed” her life.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In